← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs for urinary frequency and incontinence
oxybutynin
G04BD04
Forms & Strengths
- Oral tablet: 5 mg
- Extended-release tablet (OxyTrol/Ditropan XL): 5 mg, 10 mg, 15 mg
- Syrup: 5 mg/5 mL
- Transdermal patch: 3.9 mg/day
- Topical gel: 10 mg/g
Adult Dosing
- Immediate-release tablet/syrup: 5 mg orally 2 to 3 times daily; max 20 mg/day
- Extended-release tablet: 5 to 10 mg orally once daily; may increase by 5 mg weekly up to 30 mg/day
- Transdermal patch: Apply 3.9 mg/day patch twice weekly (every 3 to 4 days)
- Topical gel: One packet (1 g gel containing 10 mg oxybutynin) applied once daily to clean, dry, intact skin of the abdomen, upper arms, or shoulders
Pediatric Dosing
- Children < 5 years: Not recommended for overactive bladder
- Children ≥ 5 years (Immediate-release): 0.2 mg/kg orally 2 to 3 times daily
- Children ≥ 6 years (Extended-release): Initial 5 mg orally once daily; max 20 mg/day
Indications
- Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
- Neurogenic detrusor overactivity in pediatric patients aged 5 years and older
- Hyperhidrosis (off-label use for topical/oral formulations)
Mechanism of Action
- Competitive antagonist of muscarinic acetylcholine receptors (primarily M1, M2, and M3 subtypes)
- Relaxes bladder smooth muscle by inhibiting the muscarinic action of acetylcholine
- Increases bladder capacity and decreases uninhibited detrusor contractions
Contraindications
- Urinary retention
- Gastric retention
- Conditions with decreased gastrointestinal motility
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity to oxybutynin or any component
Adverse Reactions
- Xerostomia (dry mouth)
- Constipation
- Blurred vision
- Dizziness and somnolence
- Urinary tract infection
- Pruritus or application-site reactions (patch and gel)
- Cognitive impairment in elderly patients
Drug Interactions
- Anticholinergic agents (e.g., antihistamines, tricyclic antidepressants): May potentiate anticholinergic adverse effects
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May increase plasma concentrations of oxybutynin
- Prokinetic agents (e.g., metoclopramide): Anticholinergic activity may antagonize the effects of gastrointestinal prokinetics
Curated Content: Needs Vetting Before Put to Clinical Use